SCHEMBL6436398

SCHEMBL6436398

CC(C)(C)[Si](C)(C)OCN1C(=O)CC[C@H]1CCCCCl

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 1/20 0.32
PTGER2 P43116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3679333 0.80 PDK2 (0.34) PTGER3PTGER2
SCHEMBL1576228 0.69 DUT (0.34)
SCHEMBL23364138 0.68 DUT (0.37)
SCHEMBL23364135 0.68 DUT (0.37)
SCHEMBL2850230 0.68 DUT (0.33)
SCHEMBL24795965 0.68 DUT (0.33)
SCHEMBL24795959 0.68 PDK2 (0.41) PTGER3PTGER2
SCHEMBL21389332 0.68 DUT (0.33)
SCHEMBL28526467 0.68 DUT (0.33)
SCHEMBL1401084 0.68 PDK2 (0.41) PTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453503-A4 EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF MERCK & CO INC (US) 2005-03-30 EP disclosed
EP-1513589-A1 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA MERCK FROSST CANADA INC. (CA) 2005-03-16 EP disclosed
EP-1453503-A2 EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2003103772-A1 1,5-DISTRIBUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TEATMENT OF EYE DISEASES SUCH AS GLAUCOMA MERCK FROSST CANADA & CO. (CA) 2003-12-18 WO disclosed
WO-2003047417-A2 EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF MERCK & CO., INC. (US) 2003-06-12 WO disclosed